Pharmaceuticals

News Hour: French drugmaker Sanofi boosted its early-stage pipeline in immunology on Thursday by signing a deal with Ablynx that could earn the Belgian biotech firm as much as 2.4 billion euros ($2.8...

News Hour: Novartis announced that the European Medicines Agency (EMA) has accepted its Marketing Authorization Application (MAA) for AMG 334 (erenumab) for the prevention of a migraine. Erenumab is an anti-CGRP monoclonal antibody developed...

News Hour: A European Medicines Agency (EMA) panel recommended on Friday approving Novartis’s Kisqali drug, bolstering the Swiss drugmaker’s bid to challenge rival Pfizer’s Ibrance against tough-to-treat breast cancer. The EMA’s Committee for...

News Hour: Tresiba® demonstrated no increased risk of major cardiovascular (CV) events and significant reduction in rates of severe hypoglycaemia compared to insulin glargine U100 in the DEVOTE trial. DEVOTE is a long-term,...

News Hour: A Roche breast cancer drug at the center of a prolonged pricing row in Britain will now be paid for routinely, following a discount deal between the company and the National...

News Hour: For the second year in a row, Lyfebulb and Novo Nordisk will support international patient entrepreneurs who develop innovative ideas and concepts aimed to positively empower and impact the lives of...

News Hour: Novartis announced it has entered into a clinical research collaboration in which Bristol-Myers Squibb will investigate the safety, tolerability, and efficacy of Mekinist (trametinib) in combination with Opdivo (nivolumab) and Opdivo...

News Hour: The World Health Organization published a new classification of antibiotics on Tuesday that aims to fight drug resistance, with penicillin-type drugs recommended as the first line of defense while colistin should...

News Hour: Roche Holding AG’s Alecensa halted the spread of lung cancer for a median of 15 months longer than treatment with rival Pfizer Inc’s Xalkori with fewer side effects, according to trial...

News Hour: Novo Nordisk announced that the US Food and Drug Administration (FDA) has approved the Biologics License Application for REBINYN®for the treatment of adults and children with hemophilia B. “We are excited...